• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

83.98 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
July 23, 2025
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
July 22, 2025
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment. 
Via Investor's Business Daily
Merck Announces Fourth-Quarter 2025 Dividend
July 22, 2025
From Merck & Co., Inc.
Via Business Wire
MERCK & CO. INC. (NYSE:MRK) – A Quality Stock with Strong Fundamentals
July 22, 2025
MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors. 
Via Chartmill
Merck Commits To Veeva’s Vault CRM, Draws Wall Street Cheer: Retail’s Not Enthusiastic
July 21, 2025
Via Stocktwits
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided
July 21, 2025
Via Stocktwits
Merck & Co Unusual Options Activity For July 15
July 15, 2025
Via Benzinga
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic
July 15, 2025
Via Stocktwits
Does This Move Make Merck Stock a Buy?
July 20, 2025
Via The Motley Fool
Topics Intellectual Property
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?
July 20, 2025
Via The Motley Fool
Topics Economy Intellectual Property
Want Decades of Passive Income? Buy This ETF and Hold It Forever
July 19, 2025
Via The Motley Fool
Topics ETFs Regulatory Compliance Stocks
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 19, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
P/E Ratio Insights for Merck & Co
July 09, 2025
Via Benzinga
Got $200? 2 Dividend Stocks to Buy and Hold Forever
July 19, 2025
Via The Motley Fool
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business
July 17, 2025
Via The Motley Fool
Topics Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
July 16, 2025
Via Benzinga
1 Dow Jones Stock to Target This Week and 2 to Avoid
July 16, 2025
While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising costs, or disruptive new competitors. 
Via StockStory
Topics Stocks
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
July 15, 2025
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026. 
Via Benzinga
This House of Representative Just Bought Up To $30K In 3M Stock
July 15, 2025
Via Benzinga
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
July 14, 2025
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating. 
Via Benzinga
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
July 14, 2025
From Merck & Co., Inc.
Via Business Wire
AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial
July 14, 2025
AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile. 
Via Benzinga
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
July 11, 2025
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
MERCK & CO. INC. (NYSE:MRK) – A Strong Dividend Stock with Solid Fundamentals
July 11, 2025
MERCK & CO. (NYSE:MRK) offers a strong 4% dividend yield, consistent growth, and solid profitability, making it a top pick for income investors. The stock is also attractively valued. 
Via Chartmill
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
July 11, 2025
Via The Motley Fool
Topics Intellectual Property
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
July 10, 2025
From Merck & Co., Inc.
Via Business Wire
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
July 10, 2025
From Merck Sharp & Dohme
Via Business Wire
Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps
July 09, 2025
Kazia's early trial data show significant CTC and cluster reduction in a breast cancer patient treated with Paxalisib, Keytruda, and chemotherapy. 
Via Benzinga
Nvidia's $4 Trillion Milestone Lifts Wall Street: What's Moving Markets Wednesday?
July 09, 2025
Wall Street rose on Wednesday as investors shrugged off fresh trade uncertainty after the White House delayed the start of new tariffs to Aug. 1, raising hopes for new rounds of negotiations. 
Via Benzinga
Topics World Trade
Explore the top gainers and losers within the S&P500 index in today's session.
July 09, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap